Compass Delays Pivotal Trial Readouts for Psilocybin in Depression, Lays Off 30% of Staff

In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials of its psilocybin to address treatment-resistant depression.